Literature DB >> 8559343

Inhibition of in vitro meningioma proliferation after growth factor stimulation by calcium channel antagonists: Part II--Additional growth factors, growth factor receptor immunohistochemistry, and intracellular calcium measurements.

R L Jensen1, Y S Lee, M Guijrati, T C Origitano, R D Wurster, O H Reichman.   

Abstract

We have previously reported that calcium channel antagonists can block both the growth of meningiomas in culture and the potent growth stimulation of meningioma cells by epidermal growth factor (EGF) and platelet-derived growth factor (PDGF). This study further defines the nature of this growth inhibition. Primary meningioma cultures were established, and cells were characterized. Fibroblast growth factor or insulin-like growth factor-I growth stimulation in the presence of calcium channel antagonists was examined. In addition, the effects of ethylene glycol-bis-(aminoethylether) N,N,N',N"-tetraacetic acid and Bay K 8644, a calcium channel agonist, on the growth factors were analyzed. Growth factor receptor immunohistochemistry was performed on the original tumors and the in vitro meningioma cells. Twelve of 17 (71%) meningiomas in this study were positive for the EGF receptor, and 14 of 17 (82%) were positive for the PDGF receptor. Five of six (83%) of the culture cells were positive for the EGF receptor, and four of five (80%) were positive for the PDGF receptor. Intracellular calcium changes were quantified using the intracellular calcium-chelating, fluorescent dye, Fura-2. The growth stimulation of fibroblast growth factor and insulin-like growth factor-I on meningioma cells in culture was decreased in a dose-dependent manner by calcium channel antagonists. The growth stimulation of fibroblast growth factor and insulin-like growth factor-I was not affected by a reduction of extracellular calcium, whereas the growth stimulation of EGF and PDGF was. Interestingly, intracellular calcium was not increased after exposure to growth factors but was increased after serum stimulation. This increase could be blocked by preincubation with verapamil. Calcium channel antagonists can inhibit proliferation of meningioma cells in culture after stimulation with a number of growth factors. These drugs might disrupt intracellular calcium homeostasis or interfere with key elements of the growth factor signal transduction pathways. These mechanisms as well as the potential clinical relevance of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8559343     DOI: 10.1227/00006123-199511000-00013

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  8 in total

1.  In vitro growth inhibition of human colonic tumor cells by Verapamil.

Authors:  Qi-Zhen Cao; Gang Niu; Huan-Ran Tan
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

Review 2.  Platelet-derived growth factor in human brain tumors.

Authors:  M Kirsch; J C Wilson; P Black
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

Review 3.  Aberrant signaling pathways in meningiomas.

Authors:  Brian T Ragel; Randy L Jensen
Journal:  J Neurooncol       Date:  2010-09-14       Impact factor: 4.130

4.  Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas.

Authors:  Randy L Jensen; Brian T Ragel; Kum Whang; David Gillespie
Journal:  J Neurooncol       Date:  2006-04-13       Impact factor: 4.130

5.  Molecular biology of unreresectable meningiomas: implications for new treatments and review of the literature.

Authors:  Jay Jagannathan; Rod J Oskouian; Hian Kwang Yeoh; Dwight Saulle; Aaron S Dumont
Journal:  Skull Base       Date:  2008-05

6.  Verapamil inhibits tumor progression of chemotherapy-resistant pancreatic cancer side population cells.

Authors:  Lu Zhao; Yue Zhao; Bettina Schwarz; Josef Mysliwietz; Roland Hartig; Peter Camaj; Qi Bao; Karl-Walter Jauch; Makus Guba; Joachim Walter Ellwart; Peter Jon Nelson; Christiane Josephine Bruns
Journal:  Int J Oncol       Date:  2016-05-10       Impact factor: 5.650

Review 7.  Repurposing of Anticancer Stem Cell Drugs in Brain Tumors.

Authors:  Hisham F Bahmad; Darine Daher; Abed A Aljamal; Mohamad K Elajami; Kei Shing Oh; Juan Carlos Alvarez Moreno; Ruben Delgado; Richard Suarez; Ana Zaldivar; Roshanak Azimi; Amilcar Castellano; Robert Sackstein; Robert J Poppiti
Journal:  J Histochem Cytochem       Date:  2021-06-24       Impact factor: 2.479

Review 8.  The prince and the pauper. A tale of anticancer targeted agents.

Authors:  Alfonso Dueñas-González; Patricia García-López; Luis Alonso Herrera; Jose Luis Medina-Franco; Aurora González-Fierro; Myrna Candelaria
Journal:  Mol Cancer       Date:  2008-10-23       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.